Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients

Haematologica

Volumn 89, Issue 10, 2004, Pages 1172-1178

  Yavarian, Majid ^a   Karimi, Mehran ^c   Bakker, Egbert ^b   Harteveld, Cornelis L ^b   Giordano, Piero C ^b  

^a Bandar Abbas University   (Iran)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hydroxyurea; Iran; Thalassemia; Xmnl

Indexed keywords

BETA GLOBIN; GAMMA GLOBIN; HYDROXYUREA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BETA THALASSEMIA; BLOOD TOXICITY; BLOOD TRANSFUSION; CHILD; DIARRHEA; DRUG EFFICACY; FEMALE; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENETIC LINKAGE; GENETIC POLYMORPHISM; HAPLOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PERINATAL PERIOD; PROMOTER REGION; RASH; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ALLELES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FEMALE; FETAL HEMOGLOBIN; GENETIC HETEROGENEITY; GLOBINS; HAPLOTYPES; HUMANS; HYDROXYUREA; IRAN; MALE; SPLENECTOMY; TREATMENT OUTCOME;

EID: 6344240976     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. rd edition, Philadelphia, PA: WB Sounders; 2001.
2. +thalassemia. N Engl J Med 1982;307:1469-75.
3. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia. N Engl J Med 1995;332:1317-22.
4. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45.
5. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anaemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51.
6. Brachet C, Azzi N, Demulder A, Devalck C, Gourdin A, Gulbis B, et al. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome. Bone Marrow Transplant 2004;33:799-803.
7. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe β-globin disorders. Br J Haematol 1995;91:263-8.
8. Olivieri NF, Rees DC, Ginder GD, Thein SL, Waye JS, Chang L, et al. Elimination of transfusions through induction of fetal haemoglobin synthesis in Cooley's anaemia. Ann N Y Acad Sci 1998;850:100-9.
9. Kinney TR, Helms RW, O'Branki EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anaemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94: 1550-4.
10. Gebhart E. Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing. Hum Genet 1981;58:235.
11. Oppenheimer JJ, Fishbein WN. Induction of chromosome breaks in cultured normal human leucocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Res 1965;25:980.
12. Murphy ML, Chaube S. Preliminary survey of hydroxyurea (NSC-32065) as a teratogen. Cancer Chemother Rep 1964;40:1.
13. Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Arch Toxicol Suppl 1980;4:239.
14. Ziegler-Skylakakis K, Schwarz LR, Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat Res 1985;152: 225.
15. Triadou P, Maier-Redelsperger M, Krishnamoorty R, Deschamps A, Casadevall N, Dunda O, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994;36: 367.
16. Steinberg MH, Barton F, Castro O, Koshy M, Eckman J, Terrin M. Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia: effects at 6- to 7-years. Blood 1999;94:644.
17. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000;95: 3589-93.
18. de Lima PD, Cardoso PC, Khayat AS, Bahia Mde O, Burbano RR. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Genet Mol Res 2003;2:328-33.
19. Prehu C, Ducrocq R, Godart C, Rion J, Galacteros F. Determination of HbF levels: the routine method. Haemoglobin 1998; 22:459-67.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
21. Losekoot M, van Heeren H, Schipper JJ, Giordano PC, Bernini LF, Fodde R. Rapid detection of the highly polymorphic globin framework by denaturing gradient gel electrophoresis. J Med Genet 1992;29: 574-7.
22. Varawalla NY, Fitches AC, Old JM. Analysis of β-globin gene haplotypes in Asian Indians: origin and spread of beta-thalassaemia on the Indian subcontinent. Hum Genet 1992;90:443-9.
23. Sutton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applied to the determination of β-like globin gene cluster haplotypes. Am J Hematol 1989;32:66-9.
24. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Bailliére's Clin Haematol 1993;6:215-62.
25. Dimovski AJ, Adekile AD, Divoky V, Baysal E, Huisman TH. Polymorphic pattern of the (AT)x(T)y motif at -530 5 to the β-globin gene in over 40 patients homozygous for various β-thalassemia mutations. Am J Hematol 1994;45:51-7.
26. Perichon B, Ragusa A, Lapoumeroulie C, Romand A, Moi P, Ikuta T, et al. Inter-ethnic polymorphism of the β-globin gene locus control region (LCR) in sickle cell anaemia. Hum Genet 1993;91:464-8.
27. Cang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal haemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotype, α-globin gene number, gender and age. Blood 1995;85: 1111-7.
28. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single tube multiplex-PCR screen for common deletional determinants of α-thalassemia. Blood 2000;95:360-2.
29. Higgs DR, Aldridge BE, Lamb J, Clegg JB, Weatheral DJ, Hayes RJ, et al. Interaction of α-thalassemia and homozygous sickle cell disease. N Engl J Med 1982;306: 1441-6.
30. Dover GJ, Chang VT, Boyer SH, Serjeant GR, Antonarakis S, Higgs DR. The cellular basis for deferent fetal levels among sickle cell individuals with two, three and four α-globin genes. Blood 1987;69:34-4.
31. Lu ZH, Steinberg MH. Fetal haemoglobin in sickle cell anaemia: relation to regulatory sequences cis to the β-globin. Blood 1998;87:1604-11.
32. Lois D, Geogiou I, Loizou P, Makrydiams G. High HbF in pregnancy is associated with the Xmnl polymorphisms at the -158 bp of the G γ-globin gene. Eur J Obstet Gynecol Reprod Biol 1995;60:153-6.
33. Rosatelli MC, Altay C, Oner R, Leoni GB, Moi B, Atzori G, et al. β-globin haplotype and Xmnl polymorphisms at position -158 and HbF production in Fanconi's anemia. Haematologica 1992;77:106-9.
34. Shimizu K, Keino H, Terasawa T, Schichishima T, Ikuta K, Hyashi Y. Elevated haemoglobin F in Juvenile and adult chronic myelogenous leukaemia. Acta Hematol 1988;80:28-33.
35. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol 1990;27:360-76.
36. Labie D, Pagnier J, Lapoumeroulie C, Rouabbi F, Dunda-Belkhodja O, Chardin P, et al. Common haplotype dependency of high Gγ-globin gene expression and high HbF levels in β-thalassemia and sickle cell anaemia patients. Proc Natl Acad Sci USA 1985;82:2111-4.
37. Wang M, Tang DC, Liu W, Chin K, Zhu JG, Fibach E, et al. Hydroxyurea exerts bimodal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 2002;119:1098-105.
38. Amoyal I, Goldfarb A, Fibach E. Flow cytometric analysis of hydroxyurea effects on fetal haemoglobin production in cultures of β-thalassemia erythroid precursors. Haemoglobin 2003;27:77-87.
39. Fabricius E, Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol 1971;16: 679-83.
40. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998;91:1533-41.
41. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol 2004;83:430-3.
42. Yavarian M, Farshidfar GR, Safa O. Prevalence of glucose-6-phosphate dehydrogenase deficiency in the male population of the Iranian province of Hormozgan. Hormozgan Med J 2001;5:2-6.
43. Harteveld CL, Yavarian M, Zoarai A, Quakkelaar ED, van Delft P, Giordano PC. Molecular spectrum of α-thalassemia in the Iranian population of Hormozgan: Three novel point mutation defects. Am J Hematol 2003;74:99-103.
44. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease Blood 2001;97:3628-32.